Published in J Clin Oncol on November 01, 1999
Expression of galectins in cancer: a critical review. Glycoconj J (2004) 1.28
Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol (2010) 1.14
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci (2007) 1.11
What is New on Thyroid Cancer Biomarkers. Biomark Insights (2008) 0.91
Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer (2006) 0.90
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. Front Surg (2016) 0.87
Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch (2005) 0.85
Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch (2004) 0.85
Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging (2007) 0.82
Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch (2004) 0.81
Can CD10 be used as a diagnostic marker in thyroid pathology? Virchows Arch (2008) 0.79
Distinguishing molecular markers in thyroid tumors: a tribute to Dr. Orlo Clark. World J Surg (2009) 0.77
Galectin-1 is a diagnostic marker involved in thyroid cancer progression. Int J Oncol (2017) 0.77
Sensitivity and Specificity of Galectin-3 and Glypican-3 in Follicular-Patterned and Other Thyroid Neoplasms. J Clin Diagn Res (2016) 0.75
Hemithyroidectomy is the preferred initial operative approach for an indeterminate fine needle aspiration biopsy diagnosis. Can J Surg (2012) 0.75
Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncol Lett (2017) 0.75
Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma. Virchows Arch (2010) 0.75
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 2.08
Thyroid disease classification. Lancet (2000) 2.00
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer (1991) 1.95
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol (1989) 1.73
The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer (2000) 1.71
From the fetal liver to spleen and gut: the highway to natural antibody. Mucosal Immunol (2009) 1.59
Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res (1997) 1.58
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 1.55
Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol (2001) 1.54
Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet (2001) 1.54
Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer (2000) 1.50
Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res (1999) 1.46
Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol (2000) 1.44
Morphological, immunochemical, and biochemical study of rabbit achilles tendon at various ages. J Bone Joint Surg Am (1980) 1.43
Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol (1995) 1.43
Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res (2000) 1.35
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35
Comparative study of antibodies to native and denatured DNA. J Immunol (1970) 1.29
Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res (2001) 1.29
Experimental skin lesions in mice resembling systemic lupus erythematosus. Arthritis Rheum (1973) 1.27
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res (1984) 1.26
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res (1983) 1.25
Changes in Ia-like antigen expression on malignant human cells. Immunogenetics (1981) 1.22
Experimental renal disease induced by DNA-anti-DNA immune complexes. J Clin Invest (1972) 1.13
Expression of HL-A antigens in synchronized cultures of human lymphocytes. J Immunol (1972) 1.12
Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenetics (1984) 1.12
Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol (1998) 1.10
β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene (2012) 1.10
Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res (1986) 1.08
Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer (2000) 1.08
Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer (1993) 1.07
Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin. Hum Immunol (1996) 1.06
Regeneration of rabbit calcaneal tendon: a morphological and immunochemical study. Cell Tissue Res (1978) 1.06
Immune complex nephritis in Schistosoma mansoni-infected mice. Eur J Immunol (1976) 1.03
Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest (1996) 1.03
The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res (2002) 1.02
Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis. Br J Cancer (2004) 1.02
Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J Natl Cancer Inst (1981) 1.02
Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene (1995) 1.02
A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst (1982) 1.02
Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res (2000) 1.01
Distribution of laminin and collagen type-IV in benign and malignant lesions of melanocytic origin. Int J Cancer (1985) 0.99
HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Prolif (2009) 0.99
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene (2011) 0.99
Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. J Pathol (1995) 0.98
Immunochemical localization of contractile proteins in mammalian meiotic chromosomes. Cell Tissue Res (1980) 0.98
Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst (1984) 0.97
Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol (1983) 0.97
HLA-C heavy chains free of beta2-microglobulin: distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon-gamma responsiveness. Tissue Antigens (1997) 0.97
HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage. Oncogene (2011) 0.97
A primary amelanotic melanoma of the vagina diagnosed by immunocytochemistry. Int J Gynaecol Obstet (1989) 0.97
Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci (2001) 0.95
Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer (1995) 0.95
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer (1999) 0.95
Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol (1995) 0.94
Analysis of the expression of I-Ak-like antigens in murine fetal and adult tissues with the monoclonal antibody 10-2.16. Scand J Immunol (1981) 0.94
Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin. Eur J Cancer Clin Oncol (1988) 0.94
Evaluation of T cell subsets in Behçet's syndrome using anti-T cell monoclonal antibodies. Clin Exp Immunol (1985) 0.94
HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol (2000) 0.93
Rapid perinatal growth mimicking malignant transformation in a giant congenital melanocytic nevus. Hum Pathol (1991) 0.93
Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma. J Cell Biochem (2001) 0.93
Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma. Cancer Res (1984) 0.92
Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). Anticancer Res (1989) 0.92
Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. J Natl Cancer Inst (1983) 0.91
Precipitin reactions between polyribonucleotides and heat labile serum factors. J Immunol (1972) 0.91
Expression and production of tenascin in benign and malignant lesions of melanocyte lineage. Int J Cancer (1990) 0.91
Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res (1990) 0.91
Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br J Cancer (2006) 0.90
Ia-like antigens on freshly explanted human melanoma. Clin Immunol Immunopathol (1981) 0.89
Generation and characterization of the murine monoclonal antibody M-KID 2 to VLA-3 integrin. Hybridoma (1991) 0.89
Monoclonal antibodies to glutathione S-transferase pi-immunohistochemical analysis of human tissues and cancers. Int J Cancer (1991) 0.89
Malignant oncocytoma of major salivary glands. Report of a post-irradiation case. J Exp Clin Cancer Res (1998) 0.89
Multiple epitope recognition: an approach to improved radioimmunodetection of tumor-associated antigens. Int J Cancer (1987) 0.88
Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. Cancer Res (1987) 0.88
Unknown primary tumors. Biochim Biophys Acta (2011) 0.88
Tissue distribution, molecular profile, and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells. Cancer Res (1982) 0.87
Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer (1996) 0.87
Actin in the extracellular matrix of smooth muscle cells. An immunoelectron microscopic study. Connect Tissue Res (1983) 0.87
Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol (2002) 0.87
Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies. Proc Natl Acad Sci U S A (1990) 0.87
Ultrastructural and immunochemical evidence of actin in the tendon cells. Clin Orthop Relat Res (1978) 0.87
Methylation pattern of the HLA-DR alpha gene in human tissues. J Immunogenet (1990) 0.87
CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. Melanoma Res (2003) 0.87
Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Res (1991) 0.86
Isolation of soluble immune complexes from serum using protein A bearing Staphylococcus aureus bacteria: separation of the antigen from immune complex and production of antisera. Clin Immunol Immunopathol (1980) 0.86
Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines. Cancer Res (1999) 0.86
Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am J Pathol (2001) 0.86
Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J Cancer (1998) 0.85
Idiotypic replica of an anti-human tumor-associated antigen monoclonal antibody. Analysis of monoclonal Ab1 and Ab3 fine specificity. J Immunol (1989) 0.85
Wells Syndrome with Multiorgan Involvement Mimicking Hypereosinophilic Syndrome. Case Rep Dermatol (2009) 0.85
Spontaneous leptospiral infection of the rat kidney. An ultrastructural study. Exp Mol Pathol (1969) 0.85
Production and characterization of the murine monoclonal antibody 2G10 to a human T4-tyrosinase epitope. J Invest Dermatol (1991) 0.85
Recombinant human IFN-gamma, but not IFN-alpha or IFN-beta, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. J Immunol (1988) 0.84